About Us

Strive to make high quality products of stroke treatment and prevention

Company Introduction

Shanghai HeartCare Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting life and health. In the past five years, HeartCare Medical has pioneered the creation of the first one-stop solution for stroke treatment and prevention in China in the field of neurological intervention. It owns the whole product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention and hemorrhagic stroke treatment to interventional access equipment, and has applied for more than 100 patents, with an annual production capacity of more than 150,000 products, and its sales channels cover more than 1,400 hospitals in 29 provinces (including municipalities and autonomous regions) in China.

Based on the existing leading advantages, HeartCare Medical will continue to focus on popularizing new medical techniques, focus on the unmet needs of clinicians and patients in China, and operate a number of new business segments including nerve intervention, Cardiac therapy, pulmonary intervention and computer-aided technology, expecting that in these medical fields with great potential, Continuously introduce innovative interventional instruments that define new surgical methods to reduce the mortality of major diseases and improve the prognosis of patients.

5 years

COMPANY HISTORY

14

LAUNCHED PRODUCTS

100 +

PATENTS FILED

1400 +

HOSPITAL ENTRY

10 +

SOLUTION

Development path

2016.6

We were established as a limited liability company in the PRC under the name of “Shanghai Care Medical Technology Corporation Limited ”.

2019.12

We obtained NMPA registration certificates for our ExtraFlex™ distal access catheter and SupSelek™ microcatheter.

2020.8

We obtained NMPA registration certificate for our Captor™ thrombectomy device, being the first domestic multi-markers thrombectomy stent retriever in the PRC.


2020.12

We commercialized our Captor™ thrombectomy device as the first domestic multi-markers thrombectomy stent retriever in the PRC.

2020.12

We obtained NMPA registration certificate for our Fullblock™ balloon guiding catheter.

2021.1

We completed the clinical trial for our LAA occluder.

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

The board consists of 9 directors, which include 2 executive directors, 4 non-executive directors and 3 independent executive directors.

Name Position
Mr. WANG Guohui Chairman of the Board,executive Director and chief executive officer
Ms. ZHANG Kun Executive Director and deputy general manager
Mr. DING Kui Non-executive Director
Mr. LIU Yanbin Non-executive Director
Mr. CHEN Gang Non-executive Director
Mr. OUYANG Xiangyu Non-executive Director
Mr. GUO Shaomu Independent Nonexecutive Director
Mr. GUO Shaomu Independent Nonexecutive Director
Mr. GUO Shaomu Independent Nonexecutive Director

 

SENIOR MANAGEMENT:

Name Position
Mr. WANG Guohui Chairman of the Board,executive Director and chief executive officer
Ms. ZHANG Kun Executive Director and deputy general manager
Mr. LI Zhigang Deputy general manager
Mr. WEI Jiawei Deputy general manager
Mr. ZHANG Han Chief Financial Officer

Awards and Qualification

>

Our Vision